TRDA
Entrada Therapeutics, Inc.
$7.72
+0.13 (+1.71%)
At close · Jul 2
Market Cap
$299.70M
Shares
38,820,616
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.72
Open$7.67
Day$7.46–8.10
52W$4.93–16.45
Avg vol 30d306K
Short int1.9M · 4.9% float · 8.0d
Short vol33%
Last earningsMay 7, 2026
DataOct 2021–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−19% below
−
Price vs 50-day avg
−7% below
◦
RSI (14)
54 · neutral
+
MACD trend
positive
◦
52-week position
24% · mid-range
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $8 › 200d $10 — 200d above 50d
+
Institutional flow
2 of 118 funds reported for Jun 30 · net +175 sh shares
−
Insider flow
Net -$599.4K over 90 days · 67% sells
−
Short interest
4.93% of float · ▲ +10.8% MoM · 8.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
118 holders — near 3-yr high, broad support
Fundamentals
Weak
−
Revenue growth
−88% Y/Y
−
EPS growth
−307% Y/Y
−
Free cash flow
$-129.6M
+
Balance sheet
net cash $90.4M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−19% below
Bearish
Price vs 50-day avg
−7% below
Bearish
RSI (14)
54 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
24% · mid-range
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $8 › 200d $10 — 200d above 50d
Institutional flow
Accumulating
2 of 118 funds reported for Jun 30 · net +175 sh shares
Insider flow
Distributing
Net -$599.4K over 90 days · 67% sells
Short interest
Rising
4.93% of float · ▲ +10.8% MoM · 8.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
118 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $8 · 24%
52-wk high $16
vs 200-day avg -19%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRDA
this stock
Entrada Therapeutics, Inc.
|
$299.70M | -24.9% | -87.9% | — | 4.9% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRDA | +8.0% | +17.3% | -26.6% | +4.9% | -24.9% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +6.5% | +18.6% | -34.6% | +5.2% | -34.1% |